Today: 25 January 2026
Subscribe
Browse Category

NASDAQ:IMRX News 8 January 2026

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

NEW YORK, Jan 8, 2026, 08:39 EST — Premarket Shares of Immuneering Corp jumped about 24% to $8.33 in premarket trading on Thursday, after the biotech released updated survival data for its lead pancreatic cancer program. The stock last closed at $6.74. The update matters because Immuneering’s valuation hinges on whether atebimetinib can hold up as the company pushes toward…
8 January 2026
·····

Stock Market Today

  • Bunzl Shares Down 37% in a Year Despite EPS Growth
    January 25, 2026, 3:34 AM EST. Bunzl plc (LON:BNZL) investors have faced a 37% loss over the past year, while the market returned 25%. The company's share price declined 39% over 12 months and has fallen 14% in the last three months. Over three years, shares are down 31%. Despite the price drop, earnings per share (EPS) rose 0.7% in the same period, suggesting market expectations for higher growth were unmet. Revenue remained steady, possibly fueling disappointment. Insider buying has been noted, indicating confidence within the company. Long-term shareholders have experienced a modest annual loss of 0.3% over five years. Analysts will watch future earnings closely to determine if a turnaround is feasible amid continued share price weakness.
Go toTop